Background: Cardiac tumors are a very rare entity. Leiomyosarcoma represents less than 1% of cases.
Case Presentation: a 51-year-old woman diagnosed with primary left atrium leiomyosarcoma. She was treated by optimal surgery and adjuvant chemotherapy. She is still alive after a follow-up of 24 months without evidence of local or distant recurrence.
Conclusions: Cardiac leiomyosarcoma is a rare tumor with a dismal prognosis. Surgery is the mainstay of treatment. Adjuvant treatment is still controversial.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343408 | PMC |
| http://dx.doi.org/10.1186/s13569-017-0069-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary Cardiac Leiomyosarcoma Extending From Right Atrium to Inferior Vena Cava Without Metastasis: A Case Report.
Cureus
November 2024
Cardiothoracic Surgery, Albany Medical Center, Albany, USA.
A 27-year-old female with a history of acute lymphoblastic leukemia in remission presented with chest pain, liver cirrhosis, and a thrombus in the hepatic vein on ultrasound. Further workup with computed tomography (CT) and magnetic resonance imaging (MRI) revealed a mass extending from the inferior vena cava to the right atrium, 3.4 x 3.
View Article and Find Full Text PDFMinimally Invasive Image-Guided Percutaneous Irreversible Electroporation of Adrenal Metastases.
Cardiovasc Intervent Radiol
January 2025
Department of Interventional Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.
Purpose: A single-center retrospective study was performed to evaluate the safety and efficacy of minimally invasive irreversible electroporation (IRE) to treat metastatic adrenal tumors.
Materials And Methods: This single-center study, approved by the Institutional Review Board, retrospectively analyzed six patients who underwent image-guided percutaneous IRE for adrenal metastases. Pre-procedural imaging included CT, MRI and/or F-FDG PET-CT scans.
Sternotomy and extracorporal circulation for fulminant Budd-Chiari syndrome due to leiomyosarcoma of the inferior vena cava.
Cardiooncology
November 2024
Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, 44-102, Poland.
Background: Budd-Chiari syndrome is a rare and severe vascular liver disease. We presented patient with fulminant liver failure secondary to leiomyosarcoma of the IVC and thrombosis.
Case Presentation: A 44-year-old female presented with fulminant liver failure secondary to inferior vena cava (IVC) thrombosis.
Multimodality Imaging Evaluation of Tumour Peeking Its Head Into the Right Atrium.
Heart Lung Circ
December 2024
Department of Cardiovascular Medicine, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan. Electronic address:
Expect the unexpected: fulminant myocardial cytotoxic Injury from Trabectedin.
Cardiooncology
October 2024
Memorial Sloan Kettering Cancer Center | Weill Cornell Medicine, 1275 York Ave, New York, NY, 10065, USA.
Background: Trabectedin (Tbt) is an alkylating agent prescribed for soft tissue sarcomas after treatment failure of first line agents. While cardiomyopathy can occur with Tbt treatment after anthracycline exposure, Tbt-induced fulminant myocardial cytotoxic injury in the setting of other systemic cytotoxicity associated with Tbt has not been reported.
Case Presentation: 51-year-old female with hypertension, hyperlipidemia, metastatic leiomyosarcoma with progression of disease despite several lines of chemotherapy including doxorubicin-based therapy was started on Trabectedin (Tbt) 5 days prior to presentation with symptoms of fever, myalgias, arthralgias, and palpitations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!